Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bivalent Vaccine With OPT-821 and Oral β-glucan for High-Risk Neuroblastoma
NCT06057948Phase 2Recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Sep 2023
- Primary completion
- Mar 2027
- Modality
- Microbiome Therapeutics, Split/Subunit Vaccines, Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of beta-D-glucan in neuroblastoma (2 arms), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Mean antibody titer of anti-GD2 IgG1 at 32 weeks. Started Sep 2023; status: recruiting.
02
Drugs
beta-D-glucan
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on NCT06057948.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06057948.